The present invention relates to streptococcal vaccine formulations and their use in generating immunity against streptococcal infection.

The present invention relates to streptococcal vaccine formulations and their use in generating immunity against streptococcal infection.

The immune response of an animal to a target immunogen may be enhanced by use of an adjuvant which includes low concentrations of killed cells of Mycobacterium avium subspecies avium in combination with mineral oil. The adjuvant may be used in vaccine compositions for the immunization of an animal against any target immunogen and is particularly preferred for use with immunocontraceptive vaccines such as GnRH immunocontraceptive vaccines conjugated with a Blue carrier protein.

The present invention provides a method for treating canine leishmaniasis by immunotherapy.

The present disclosure relates to a fully liquid immunogenic composition comprising a combination of antigens/immunogens. The immunogenic composition comprises optimum amount of antigens/immunogens to confer protection against a number of diseases. The composition exhibits improved immunogenicity and stability. A process for preparing the vaccine composition is also disclosed.

This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.

Field of application: the invention relates to veterinary medicine and, in particular, to vaccinology and pharmacy, and is intended for the prevention and treatment of infectious and other diseases of humans and animals, where low allergenic low reactogenic vaccination is used. The essence of the invention: developed vaccines with increased immunogenicity, low allergenicity and reactogenicity, containing antigen/toxin and adjuvant, wherein that they contain vaccine antigen/toxin inactivated by electromagnetic radiation in the ultraviolet and visible regions of the spectrum in the presence of a solution of photosensitizer and salts of divalent metals, and then covalently modified according to the residues of amino groups and hydroxyls groups of antigen/toxin available for modification, at least two modifying agents at the same time in terms of 0.01-10.0% of the mass concentration of the antigen/toxin protein, and as an adjuvant it contains hydrosol hydroxide ferric chloride.

The present invention relates to microorganisms comprising each of each of an ApxIA, ApxIIA and ApxIIIA toxin, related vaccines and methods of production thereof, as well as uses thereof for the immunisation and protection of mammals.

The present invention relates to the field of neisserial vaccine compositions (particularly gonococcal vaccine compositions) and the use of such compositions in medicine. More particularly, the present invention relates to genetically modified gonococci of strain FA1090 and outer membrane vesicles obtained therefrom. The invention also provides a process for preparing the genetically modified gonococci of the invention as well as immunogenic compositions and vaccines comprising the outer membrane vesicles of the invention.

The invention refers to a composition comprising inactivated cells deficient in LPS from the genus Acinetobacter and/or outer membrane vesicles form the same and their use for the manufacture of a medicament, preferably a vaccine, for the prevention of diseases produced by organisms of the genus Acinetobacter.